Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Mar;8(Suppl 2):S162-S163.
doi: 10.21037/tcr.2018.12.33.

Bevacizumab in recurrent glioblastoma

Nina L Martinez  1 , Jon Glass  1 , Wenyin Shi  2
Affiliations
Editorial

Bevacizumab in recurrent glioblastoma

Nina L Martinez et al. Transl Cancer Res. 2019 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2018.12.33). The authors have no conflicts of interest to declare.

Comment on

References

    1. Cohen MH, Shen YL, Keegan P, et al. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009;14:1131-8. 10.1634/theoncologist.2009-0121 - DOI - PubMed
    1. van den Bent MJ, Klein M, Smits M, et al. Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. Lancet Oncol 2018;19:1170-9. 10.1016/S1470-2045(18)30362-0 - DOI - PubMed
    1. Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 2014;15:943-53. 10.1016/S1470-2045(14)70314-6 - DOI - PubMed
    1. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014;370:699-708. 10.1056/NEJMoa1308573 - DOI - PMC - PubMed
    1. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014;370:709-22. 10.1056/NEJMoa1308345 - DOI - PubMed